FindTrial
Sign In

TAS3351

DRUG2 trials

Sponsors

Taiho Oncology Inc., Taiho Oncology Inc., Taiho Oncology, Inc.

Conditions

Non-Small Cell Lung CancerPatients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.

Phase 1

A Study of TAS3351 in NSCLC Patients With EGFRmt
TerminatedNCT05765734
Taiho Oncology, Inc.Non-Small Cell Lung Cancer
Start: 2023-05-25End: 2025-03-14Updated: 2026-04-02
A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations
CompletedCTIS2022-502595-23-00
Taiho Oncology Inc., Taiho Oncology Inc.Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.
Start: 2024-05-21End: 2025-04-17Target: 35Updated: 2024-08-21